Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884756 | 0.81 | CYP11B1 (0.35) | CYP11B1CYP11B2NPSR1GRM5ADORA3 | |
| SCHEMBL2720194 | 0.80 | NPC1 (0.34) | — | |
| SCHEMBL8548870 | 0.79 | NPSR1 (0.33) | CYP11B1CYP11B2NPSR1GRM5ADORA3 | |
| SCHEMBL3500675 | 0.75 | CYP11B1 (0.33) | CYP11B1CYP11B2NPSR1 | |
| SCHEMBL5447440 | 0.75 | CYP19A1 (0.36) | CYP11B1CYP11B2NPSR1ADORA3 | |
| SCHEMBL5326782 | 0.75 | BRD4 (0.32) | CYP11B1CYP11B2NPSR1ADORA3 | |
| SCHEMBL8006029 | 0.75 | P2RX7 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL8022922 | 0.75 | NOTUM (0.36) | CYP11B1CYP11B2ADORA2A | |
| SCHEMBL7588677 | 0.75 | PTGS1 (0.41) | CYP11B1CYP11B2 | |
| SCHEMBL20843905 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258167-B2 | Naphthylmethylimidizoles as therapeutic agents | ALLERGAN, INC (US) | 2012-09-04 | — | — | US | disclosed |
| US-8013169-B2 | Naphthylmethylimidizoles as therapeutic agents | ALLERGAN, INC (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2296648-A1 | NAPHTHYLMETHYLIMIDIZOLES FOR THE TREATMENT OF STRESS URINARY INCONTINENCE | Allergan, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009140137-A9 | NAPHTHYLMETHYLIMIDIZOLES FOR THE TREATMENT OF STRESS URINARY INCONTINENCE | ALLERGAN, INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100004305-A1 | NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2010-01-07 | — | — | US | disclosed |
| WO-2009140137-A1 | NAPHTHYLMETHYLIMIDIZOLES FOR THE TREATMENT OF STRESS URINARY INCONTINENCE | ALLERGAN, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-20090286842-A1 | NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2008086131-A1 | NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286842-A1 | NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | NQO1, HNMT, ALPI | CYP11B1 234/4885CYP11B2 151/4885NPSR1 753/4885 |
| US-20100004305-A1 | NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALPI, ALPP, NCL | CYP11B1 198/4885CYP11B2 121/4885NPSR1 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.